11-16 | Unjust monopoly blocks access to treatment for millions of people with hepatitis C The Chinese Patent Re-examination Board (PRB) held a vital public hearing today on Médecins Sans Frontières’ (MSF) request to invalidate the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir.
11-16 | Unjust monopoly blocks access to treatment for millions of people with hepatitis C The Chinese Patent Re-examination Board (PRB) held a vital public hearing today on Médecins Sans Frontières’ (MSF) request to invalidate the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir.
10-20 | ©MSF Calls on US pharma corporation Johnson & Johnson to cut key TB drug price in half People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment
9-25 | Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB As global leaders gather for the first-ever United Nations tuberculosis (TB) Summit in New York this week, Médecins Sans Frontières (MSF)/Doctors Without Borders called on governments to save more lives by scaling up TB testing and treatment today, and make real commitments to develop more effective and easier-to-use tools to defeat TB tomorrow. New global TB figures released last week by
7-23 | As the annual global HIV/AIDS conference gets underway in Amsterdam, Médecins Sans Frontières (MSF) called out ViiV Healthcare—a division of US and UK pharmaceutical corporations Pfizer and GlaxoSmithKline plus Japan’s Shionogi—for preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir. The World Health Organization (WHO) now recommends dolutegravir as a preferred treatment option for adults and for children from four weeks to ten years of age, to replace pediatric treatments containing sub-optima